If you have been reading about GW501516 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-04-29. Where a claim depends on a specific study, the study is described rather than over-claimed.
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
Laboratory detection of cardarine typically involves sample preparation followed by chromatographic separation and mass spectrometric identification. Urine is the most common matrix for anti-doping tests, though blood and hair have also been explored. Methods can target the parent compound or its metabolites, depending on the expected window of detection. Reference standards are required for accurate quantification. Matrix effects and dilution can influence results, so laboratories use internal standards and validation protocols. The exact detection window varies with dose, route, and individual metabolism.
A common misconception is that cardarine has been proven safe for human use. In reality, human clinical data are limited, and long-term animal studies have raised concerns about cancer. Another misconception is that it is a supplement or vitamin-like compound. It is a synthetic research chemical with no approved medical indication. Scientific discussion often focuses on its mechanism and detection rather than therapeutic use. Regulatory and anti-doping literature treats it primarily as a prohibited substance.
Cardarine is explicitly prohibited by the World Anti-Doping Agency under the class of PPARδ agonists. Its presence in urine or blood samples can be detected using mass spectrometry-based methods, often liquid chromatography-tandem mass spectrometry. Athletes who test positive may face sanctions, including bans from competition. The compound is also regulated as a prescription-only or unapproved drug in many countries. Enforcement varies by jurisdiction, and some regions treat it as a controlled substance. Online sales may occur despite these restrictions, creating quality and legal risks.
| Property | Value | Notes |
|---|---|---|
| Solubility | Soluble in dimethyl sulfoxide and some organic solvents; practically insoluble in water | Solvent choice affects laboratory handling |
| Typical storage | -20 °C, desiccated, protected from light | Common condition for research samples |
| Analytical method | Liquid chromatography–tandem mass spectrometry (LC-MS/MS) | Used for identification and quantification in biological or product samples |
| Common synonyms | GW501516, GW-501516, GSK-516, Endurobol | Names found in research and anti-doping literature |
| Regulatory status | Unapproved therapeutic; prohibited in competitive sport | Status can vary by country and context |
Cardarine is a common name for GW501516, a synthetic compound studied for its effects on lipid and glucose metabolism. It functions as an agonist at peroxisome proliferator-activated receptor delta, or PPARδ, a nuclear receptor that influences gene expression. The molecule is not a steroid, nor is it a selective androgen receptor modulator. It is also known in research and sports literature as GW-501516 and endurobol. Early laboratory work examined its metabolic activity in cell cultures and animal models.
Activation of PPARδ changes transcription of genes involved in fatty acid transport, mitochondrial function, and skeletal muscle fuel preference. In rodent studies, pharmacological PPARδ activation was associated with increased endurance and altered body composition. These findings generated interest in performance enhancement, but species differences and study designs limit direct extrapolation to humans. Small human trials were conducted in the 2000s and later discontinued. The extent to which cardarine produces similar metabolic or performance effects in people remains an open question.
The compound is typically described as a laboratory compound rather than a therapeutic product. Published reports have explored its role in lipid disorders, insulin sensitivity, and exercise metabolism, yet no major drug regulator has approved it for medical use. Commercial samples sold under the cardarine name may vary in purity and identity. Analytical confirmation is therefore necessary when the material is discussed in scientific or regulatory contexts. Its classification as a prohibited substance in sport further shapes how it is studied and reported.
Cardarine is the common name for GW501516, a synthetic compound studied as a peroxisome proliferator-activated receptor delta agonist. Researchers developed it to explore treatments for lipid disorders and metabolic conditions. It is not an approved medicine in any country. Early clinical work examined changes in HDL cholesterol and triglycerides, but development was discontinued after animal studies raised concerns about cancer. The compound remains available as a research chemical and appears in discussions of performance enhancement.
At the molecular level, GW501516 binds and activates PPARδ, a nuclear receptor that regulates transcription. Activation shifts expression of genes involved in fatty acid oxidation, energy expenditure, and lipid transport in skeletal muscle and liver. Animal studies report increased endurance and altered lipid profiles after exposure. Human data are limited to small trials and do not establish long-term safety or efficacy. PPARδ also has roles in cell proliferation, so the relationship between activation and cancer risk remains an open question.
Published literature on cardarine includes in vitro assays, rodent experiments, and a small number of human studies. Reports describe effects on exercise capacity and lipid metabolism in animals, while human evidence is sparse. Many online descriptions present the compound as a proven endurance aid, a claim not supported by regulatory approval or large clinical trials. Analytical studies focus on identifying the parent compound and its metabolites in biological samples. Important uncertainties include species differences, dose-response relationships, and the relevance of rodent tumor findings to humans.
The harm reduction policy of Switzerland and its emphasis on the medicalisation of the heroin problem seems to have contributed to the image of heroin as unattractive for young people." Also, the notion that patients in such treatment programs are enabled to maintain "destructive behavior" contradicts the findings that patients significantly recover in terms of both their social and health situation. A clinical follow-up report on the German study on this matter found that 40% of all patients and 68% of those able to work had found employment after four years of treatment. Some even started a family after years of homelessness and delinquency.
== Remote monitoring and control == Modern refrigerated containers are often equipped with a telematic control unit and a GPS tracking unit that enables remote monitoring of the container's parameters as part of a fleet telematics system. This integration is part of the fleet digitalization of the logistics industry, making the container an element of a larger Vehicle tracking system. The system allows a fleet management operator to track the container's location and monitor internal parameters such as temperature, humidity, and door status. This continuous stream of telemetry provides a complete track and trace record of the container's temperature throughout its journey, which helps ensure the integrity of the cold chain. If the temperature deviates from the set point, the system can send an automatic alert to the operator, allowing for immediate intervention. These systems also allow for remote control, enabling an operator to change the temperature settings or turn the refrigeration unit on or off from a central software platform.
=== Dried fruit === Dried fruit is fruit from which the majority of the original water content has been removed, either naturally, through sun drying, or through the use of specialized dryers or dehydrators. Dried fruit has a long tradition of use dating back to the fourth millennium BC in Mesopotamia, and is prized because of its sweet taste, nutritive value, and long shelf life.
==== Skin conditions ==== UV rays also treat certain skin conditions. Modern phototherapy has been used to successfully treat psoriasis, eczema, jaundice, vitiligo, atopic dermatitis, and localized scleroderma. In addition, UV radiation, in particular UVB radiation, has been shown to induce cell cycle arrest in keratinocytes, the most common type of skin cell. As such, sunlight therapy can be a candidate for treatment of conditions such as psoriasis and exfoliative cheilitis, conditions in which skin cells divide more rapidly than usual or necessary.
Sources: en.wikipedia.org
The chain catshark or chain dogfish (Scyliorhinus retifer) is a small, reticulated catshark that is biofluorescent. The species is common in the Northwest Atlantic, Gulf of Mexico, and Caribbean. It is harmless and rarely encountered by humans. It has very similar reproductive traits to the small-spotted catshark (S. canicula).
To get fair wages beyond the national minimum wage, and award wage scales, unions and employers may collectively bargain. Unlike most wealthy OECD countries, Australia's collective bargaining system is largely confined to individual enterprises, rather than multi-employer bargaining. Combined with weak protections for union organising, this means that coverage of collective agreements was just 15% in 2022, compared to coverages typically over 80% in wealthier European Union member states that promote sectoral collective bargaining. Under the Fair Work Act 2009 sections 247–252, the Fair Work Commission may authorise "single interest employers" to bargain, which can include a corporate group, or multiple entities in a joint venture or common enterprise, but usually separate organisations bargain separately, if at all. Under section 186, the FWC may approve multi-employer agreements, but must find that the "agreement has been genuinely agreed to by each employer" with "no person coerced", even though solidarity strike action is unlawful in Australia. This makes multi-employer agreements rare and the coverage for fair wage agreements historically low. Employees of several employers may also ask the FWC for a special "low-paid bargaining" authorisation under sections 241 to 246, if worker pay is particularly bad and bargaining power weak, but even then employees do not have a right to take collective action. Under sections 260–265, the FWC may make a low pay determination if bargaining does not work, but in practice no multi-employer agreements have resulted.
Verbena officinalis var. africana (R. Fern. & Verdc.) Munir (=V. officinalis ssp. africana R.Fern. & Verdc.) Verbena officinalis var. eremicola Munir Verbena officinalis var. gaudichaudii Briq. Verbena officinalis var. macrostachya (F. Muell.) Benth. (=V. macrostachya) Verbena officinalis var. monticola Munir Verbena officinalis var. officinalis L. (=V. domingensis) The Texas vervain (V. halei) is sometimes included in V. officinalis as a subspecies or variety. But despite the outward similarity, biogeography alone strongly suggests there is really no justification to include this North American native here, and DNA sequence data agrees. Instead, V. halei seems to be closely related to V. macdougalii, perhaps with some interbreeding with the V. menthifolia lineage which might explain its Common Vervain-like traits.
Sources: en.wikipedia.org
== Cost == Monoclonal antibodies are more expensive to manufacture than small molecules due to the complex processes involved and the general size of the molecules, all in addition to the enormous research and development costs involved in bringing a new chemical entity to patients. They are priced to enable manufacturers to recoup the typically large investment costs, and where there are no price controls, such as the United States, prices can be higher if they provide great value. Seven University of Pittsburgh researchers concluded, "The annual price of mAb therapies is about $100,000 higher in oncology and hematology than in other disease states", comparing them on a per patient basis, to those for cardiovascular or metabolic disorders, immunology, infectious diseases, allergy, and ophthalmology.
=== Regulation of respiration === Carbon dioxide is one of the mediators of local autoregulation of blood supply. If its concentration is high, the capillaries expand to allow a greater blood flow to that tissue. Bicarbonate ions are crucial for regulating blood pH. A person's breathing rate influences the level of CO2 in their blood. Breathing that is too slow or shallow causes respiratory acidosis, while breathing that is too rapid leads to hyperventilation, which can cause respiratory alkalosis. Although the body requires oxygen for metabolism, low oxygen levels normally do not stimulate breathing. Rather, breathing is stimulated by higher carbon dioxide levels. As a result, breathing low-pressure air or a gas mixture with no oxygen at all (such as pure nitrogen) can lead to loss of consciousness without ever experiencing air hunger. This is especially perilous for high-altitude fighter pilots. It is also why flight attendants instruct passengers, in case of loss of cabin pressure, to apply the oxygen mask to themselves first before helping others; otherwise, one risks losing consciousness. The respiratory centers try to maintain an arterial CO2 pressure of 40 mmHg. With intentional hyperventilation, the CO2 content of arterial blood may be lowered to 10–20 mmHg (the oxygen content of the blood is little affected), and the respiratory drive is diminished. This is why one can hold one's breath longer after hyperventilating than without hyperventilating.
=== Screening glucose challenge test === The screening glucose challenge test (sometimes called the O'Sullivan test) is performed between 24 and 28 weeks and can be seen as a simplified version of the oral glucose tolerance test (OGTT). No previous fasting is required for this screening test, in contrast to the OGTT. The O'Sullivan test involves drinking a solution containing 50 grams of glucose and measuring blood levels one hour later. If the cut-off point is set at 140 mg/dL (7.8 mmol/L), 80% of women with GDM will be detected. If this threshold for further testing is lowered to 130 mg/dL, 90% of GDM cases will be detected, but there will also be more women who will be subjected to a consequent OGTT unnecessarily.
Sources: en.wikipedia.org
It binds and activates PPARδ, a nuclear receptor that influences gene expression related to fatty acid metabolism and energy balance. This mechanism has been studied mainly in animals and cell models, not established as a safe human therapy.
No. It is not an anabolic-androgenic steroid; it is a synthetic PPARδ agonist. Because it is banned in sport, it is sometimes grouped with doping agents even though its chemical class differs from steroids.
Human data are limited and development was discontinued, so major effects and long-term risks are not well characterized. Some early studies examined metabolic markers, but they do not provide a basis for unsupervised use.
Yes, WADA prohibits cardarine as a PPARδ agonist. It appears on the prohibited list and can be detected in urine or blood. Athletes using it risk sanctions.